China Contract Research Organization (CRO) Industry Report, 2015-2018
  • July 2015
  • Hard Copy
  • USD $2,300
  • Pages:101
  • Single User License
    (PDF Unprintable)       
  • USD $2,100
  • Code: ZLC021
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,500

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of 25.9%. With so many favorable policies, especially when a number of well-known proprietary drugs are about to expire, China’s CRO market size is expected to continue to grow by around 20% in the years ahead, to an estimated RMB 83.2 billion by 2018.

At present, some European and American CRO enterprises represented by Quintiles and Covance have penetrated the Chinese market by establishing branches or through acquisition and cooperation. These foreign giants, which occupy the majority of China’s CRO market share, are driving the industry to develop toward standardization.

There are more than 500 Chinese CRO enterprises, such as WuXi AppTec, Tigermed Consulting, Boji Medical Biotechnological, and HD Biosciences, which have a relatively large scale and develop very well. In 2014, WuXi AppTec represented a 9.69% market share while Tigermed Consulting and Boji Medical Biotechnological accounted for 1.47% and 0.34%, respectively.
As a leader in China’s CRO industry, WuXi AppTec posted revenue of RMB4.1266 billion (equivalent to USD674.3 million) in 2014, up 16.6% from a year earlier. In recent years, the company has seen rapid expansion by acquiring AppTec, ABGENT, Shanghai Medkey Med-Tech Development Co., and NextCODE Health.

Tigermed Consulting is a CRO company that specializes in the services related to clinical trials and clinical research. In 2014, the company recorded RMB624.6 million in revenue, up as high as 85.6%. In August 2012, the company completed its IPO, and then continuously strengthened its competitiveness through M&A and investment in subsidiaries. During 2013-2014, Tigermed Consulting founded Fantastic Bioimaging, Shanghai Tigermed Consulting Co., Hangzhou Talent MedCinsultant, and Tigermed-IntelliPV Ltd., and purchased BDM and Frontage Labs. In 2015, the company announced a proposed acquisition of Beiyi Renzhi (Beijing) Medical Technology Development Co. and DreamCIS Inc, a South Korean company.

Boji Medical Biotechnological, a comprehensive CRO company, was publicly traded on GEM of Shenzhen Stock Exchange in April 2015. As of the end of 2014, it had provided an accumulated more than 400 clinical research services and over 200 preclinical research services. In recent years, it has begun to focus on international expansion, successively undertaking the service projects of some overseas companies including Sweden’s Astrom Research International and South Korea’s Hyundai Pharmaceutical.

cro 英文_副本.png

China Contract Research Organization (CRO) Industry Report, 2015-2018 is mainly all about the following:
20120114.gifStatus quo, related policies, market size, competitive landscape, development trends, etc. of China’s CRO industry;
20120114.gifDevelopment environment of China’s CRO industry, including international environment, industry environment, and regional market;
20120114.gifOperation, R&D and investment, development in China, etc. of 5 global and 13 Chinese CRO companies;
20120114.gifDevelopment prediction of China’s CRO industry as well as operation of major enterprises.

1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2. Overview of China CRO Market
2.1 Status Quo
2.2 Related Policies
2.3 Market Size
2.4 Competitive Landscape
2.5 Development Trends
2.5.1 Industrial Chain Improvement 
2.5.2 Internationalization of Qualification Certification Standard
2.5.3 Development Driven by Technical Innovation

3. Development Environment of China CRO Industry
3.1 International Environment
3.1.1 Development History
3.1.2 Development Status
3.1.3 Major Countries and Regions
3.2 Industry Environment
3.3 Regional Market
3.3.1 Beijing
3.3.2 Shanghai
3.3.3 Chengdu

4. Key Chinese CRO Players
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Investment and Development
4.1.6 Forecast and Outlook
4.2 Hangzhou Tigermed Consulting Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Forecast and Outlook
4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Forecast and Outlook
4.4 ShangPharma Corp
4.4.1 Profile
4.4.2 Operation
4.4.3 Gross Margin
4.5 China Medical Technologies Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 Development
4.6 Asymchem
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Forecast and Outlook
4.7 HD Biosciences
4.7.1 Profile
4.7.2 Operation
4.7.3 Development
4.8 Porton
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Forecast and Outlook
4.9 Others
4.9.1 Shanghai Mediclon Inc.
4.9.2 Sundia MediTech Company Ltd.
4.9.3 Guangzhou Yushi Medicinal Technology Co., Ltd.
4.9.4 JOINN Laboratories (Beijing) 

5. Key Foreign CRO Companies
5.1 Covance
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Development in China
5.2 Parexel
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development in China
5.3 Quintiles
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Development in China

6. Development and Outlook
6.1 Industry Development Prediction
6.2 Operation of Major CRO Companies
6.2.1 Revenue
6.2.2 Net Income
6.2.3 Gross Margin
Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Research Application of New Drugs in China, 2010-2014
China’s Policies on CRO Industry, 2001-2015 
Market Size and YoY Growth of China’s CRO Industry, 2007-2014 
Layout of Major Global CRO Companies in Asia
Distribution of Major Foreign CRO Companies in China
Business Mode of Chinese CRO Companies 
Market Share of China’s CRO Industry by Company, 2014 
R&D Costs of International Pharmaceutical Giants, 2009-2014 
Sales of Global Top 10 Pharmaceutical Companies, 2014
Market Size and YoY Growth of Global CRO Industry, 2007-2014 
Market Share of Global CRO Industry by Region, 2014 
Revenue and Total Profit of Chinese Pharmaceutical Enterprises, 2010-2014
Revenue of Chinese Pharmaceutical Enterprises by Province, 2014
Major Regions and Characteristics of China’s Pharmaceutical Industry, 
Capital Transactions and Disclosed Amount of Biomedical Industry in Beijing, 2014
Revenue and YoY Growth of Enterprises under ABO Alliance, 2007-2014 
Initiators of Zhongguancun CRO Alliance (Listed Randomly)
Platform Advantages of Zhangjiang Drug Valley
List of Major CRO Companies in Zhangjiang Drug Valley
Business Areas Distribution of WuXi AppTec
WuXi AppTec’s Revenue and Net Income, 2010-2015 
WuXi AppTec’s Revenue Breakdown by Business, 2010-2015 
WuXi AppTec’s Revenue Structure by Business, 2010-2015 
WuXi AppTec’s Revenue Breakdown by Region, 2010-2014 
WuXi AppTec’s Revenue Structure by Region, 2010-2014 
WuXi AppTec’s Gross Margin, 2010-2015 
WuXi AppTec’s Gross Margin by Business, 2010-2015 
WuXi AppTec’s Revenue and Net Income, 2013-2018E
Revenue and Net Income of Tigermed Consulting, 2010-2015 
Tigermed Consulting’s Revenue Breakdown by Business, 2013-2014
Tigermed Consulting’s Revenue Structure by Business, 2013-2014 
Tigermed Consulting’s Revenue Breakdown by Region, 2010-2014 
Tigermed Consulting’s Revenue Structure by Region, 2010-2014 
Tigermed Consulting’s Gross Margin, 2010-2015 
Tigermed Consulting’s Gross Margin by Region, 2010-2014
Tigermed Consulting’s R&D Costs and % of Total Revenue, 2011-2014 
Tigermed Consulting’s Revenue and Net Income, 2014-2018E
Boji Medical Biotechnological’s Revenue and Net Income, 2011-2015 
Boji Medical Biotechnological’s Revenue Breakdown by Business, 2011-2014 
Boji Medical Biotechnological’s Revenue Structure by Business, 2011-2014 
Boji Medical Biotechnological’s Revenue Breakdown by Region, 2011-2014 
Boji Medical Biotechnological’s Gross Margin, 2011-2015 
Boji Medical Biotechnological’s Gross Margin by Business, 2011-2014 
R&D Costs and % of Total Revenue of Boji Medical Biotechnological, 2011-2014 
Major Service Content of Boji Medical Biotechnological
Boji Medical Biotechnological’s Subsidiaries and Their Main Business
Fundraising Projects of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2018E
ShangPharma Corp’s Organization Structure
ShangPharma Corp’s Revenue and Net Income, 2009-2014 
ShangPharma Corp’s Gross Margin, 2009-2014 
Revenue and Net Income of China Medical Technologies, 2010-2015 
Gross Margin of China Medical Technologies, 2010-2015 
Asymchem’s Revenue and Net Income, 2011-2014 
Asymchem’s Revenue Breakdown by Business, 2011-2014 
Asymchem’s Revenue Structure by Business, 2011-2014 
Asymchem’s Gross Margin, 2011-2014 
Asymchem’s R&D Costs and % of Total Revenue, 2011-2013 
Asymchem’s Major Subsidiaries and Offices
Asymchem’s Orders by Type, 2011-2013 
Asymchem’s Proposed Fundraising Project through IPO, May 2014
Asymchem’s Revenue and Net Income, 2013-2018E
HD Biosciences’ Revenue and Net Income, 2013-2014 
HD Biosciences’ Total Assets and Liabilities, 2013-2014 
Porton’s Revenue and Net Income, 2010-2015 
Porton’s Revenue Breakdown by Region, 2010-2015 
Porton’s Revenue Structure by Region, 2010-2014 
Porton’s Gross Margin, 2010-2015 
Porton’s Gross Margin by Region, 2010-2014 
Porton’s R&D Costs and % of Total Revenue, 2012-2014 
Porton’s Fundraising Project
Porton’s Revenue and Net Income, 2014-2018E
Covance’s Revenue and Net Income, 2009-2014 
Covance’s Revenue Breakdown by Business, 2009-2014 
Covance’s Revenue Structure by Business, 2009-2014 
Covance’s Revenue Breakdown by Region, 2011-2014 
Covance’s Revenue Structure by Region, 2011-2014 
Covance’s Gross Margin, 2009-2014 
Parexel’s Revenue and Net Income, 2009-2014 
Parexel’s Revenue Breakdown by Business, 2009-2014 
Parexel’s Revenue Structure by Business, 2009-2014 
Parexel’s Revenue Breakdown by Region, 2009-2014 
Parexel’s Revenue Structure by Region, 2009-2014 
Quintiles’ Revenue and Net Income, 2010-2015 
Quintiles’ Revenue Breakdown by Business, 2010-2015 
Quintiles’ Revenue Structure by Business, 2010-2015 
Quintiles’ Revenue Breakdown by Region, 2010-2015 
Quintiles’ Revenue Structure by Region, 2010-2014 
Quintiles’ Gross Margin, 2010-2015 
Charles River’s Revenue and Net Income, 2010-2015 
Charles River’s Revenue Breakdown by Business, 2013-2015 
Charles River’s Revenue Structure by Business, 2013-2015 
Charles River’s Revenue Breakdown by Region, 2011-2014 
Charles River’s Revenue Structure by Region, 2011-2014 
Charles River’s Gross Margin, 2010-2015 
PPD’s Revenue and Net Income, 2008-2011 
PPD’s Revenue Breakdown by Business, 2008-2011 
PPD’s Revenue Structure by Business, 2008-2011 
Global Proprietary Drugs Having Expired or to Expire, 2014-2016 
Market Share and YoY Growth Rate of China’s CRO Industry, 2014-2018E
Revenue of Major Chinese CRO Companies, 2010-2014 
Net Income of Major Chinese CRO Companies, 2010-2014 
Net Profit Margin of Major Chinese CRO Companies, 2010-2014 
Gross Margin of Major Chinese CRO Companies, 2010-2014 

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号